NASDAQ:BCAX Bicara Therapeutics (BCAX) Stock Price, News & Analysis $9.40 -0.20 (-2.07%) As of 03:48 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Bicara Therapeutics Stock (NASDAQ:BCAX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bicara Therapeutics alerts:Sign Up Key Stats Today's Range$9.11▼$9.5850-Day Range$7.93▼$23.6452-Week Range$7.87▼$30.99Volume538,711 shsAverage Volume771,833 shsMarket Capitalization$624.13 millionP/E RatioN/ADividend YieldN/APrice Target$30.33Consensus RatingModerate Buy Company Overview Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses.The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression. The candidate is being studied in clinical trials, including in head and neck cancer.Bicara is based in the Boston area and was established in 2018. Its chief executive officer is Christopher McNulty.AI Generated. May Contain Errors. Read More Bicara Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreBCAX MarketRank™: 3.128903654485 of 5 starsBicara Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 339th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBicara Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.72, and is based on 2 strong buy ratings, 11 buy ratings, 3 hold ratings, and 2 sell ratings.Upside PotentialBicara Therapeutics has a consensus price target of $30.33, representing about 223.3% upside from its current price of $9.38.Amount of Analyst CoverageBicara Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Bicara Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Bicara Therapeutics are expected to decrease in the coming year, from ($3.82) to ($4.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bicara Therapeutics is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bicara Therapeutics is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBicara Therapeutics has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted17.29% of the float of Bicara Therapeutics has been sold short.Short Interest Ratio / Days to CoverBicara Therapeutics has a short interest ratio ("days to cover") of 3.84, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bicara Therapeutics has recently decreased by 4.24%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBicara Therapeutics does not currently pay a dividend.Dividend GrowthBicara Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.30 News SentimentBicara Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Bicara Therapeutics this week, compared to 5 articles on an average week.Search Interest13 people have searched for BCAX on MarketBeat in the last 30 days. This is an increase of 160% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Bicara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $400,750.00 in company stock.Percentage Held by Insiders13.80% of the stock of Bicara Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsBicara Therapeutics has minimal institutional ownership at this time.Read more about Bicara Therapeutics' insider trading history. Receive BCAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCAX Stock News HeadlinesResearch Analysts Set Expectations for BCAX FY2026 EarningsNovember 15 at 10:30 AM | americanbankingnews.comWhat is HC Wainwright's Forecast for BCAX Q1 Earnings?November 14, 2026 | americanbankingnews.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 18 at 1:00 AM | Behind the Markets (Ad)Bicara Therapeutics (NASDAQ:BCAX) Stock Gets Price Target Trim from HC WainwrightNovember 14, 2026 | americanbankingnews.comBicara Therapeutics (NASDAQ:BCAX) Stock Price Target Cut by Stifel NicolausNovember 12, 2026 | americanbankingnews.comBicara Therapeutics (NASDAQ:BCAX) Stock Price Target Cut by Morgan StanleyNovember 12, 2026 | americanbankingnews.comBTIG Research Issues Pessimistic Forecast for Bicara Therapeutics (NASDAQ:BCAX) Stock PriceNovember 12, 2026 | americanbankingnews.comBicara Therapeutics Inc (BCAX) Q3 2026 Earnings Call Highlights: Strong Enrollment Momentum and ...November 10, 2026 | finance.yahoo.comSee More Headlines BCAX Stock Analysis - Frequently Asked Questions How have BCAX shares performed this year? Bicara Therapeutics' stock was trading at $16.83 at the start of the year. Since then, BCAX shares have decreased by 44.3% and is now trading at $9.3810. How were Bicara Therapeutics' earnings last quarter? Bicara Therapeutics Inc. (NASDAQ:BCAX) released its quarterly earnings data on Monday, November, 9th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.22. Read the conference call transcript. When did Bicara Therapeutics IPO? Bicara Therapeutics (BCAX) raised $298 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 17,500,000 shares at a price of $16.00-$18.00 per share. Who are Bicara Therapeutics' major shareholders? Top institutional shareholders of Bicara Therapeutics include State Street Corp (3.11%), Bellevue Group AG (1.09%), Nan Fung Trinity HK Ltd. (0.65%) and Goldman Sachs Group Inc. (0.61%). Insiders that own company stock include Ra Capital Management, LP, Claire Mazumdar, Ryan Cohlhepp, Ivan Hyep and David Raben. View institutional ownership trends. How do I buy shares of Bicara Therapeutics? Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/09/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 3 weeks, BCAX's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BCAX Previous SymbolNASDAQ:BCAX CIK2023658 Webwww.bicara.com Phone(617) 468-4219FaxN/AEmployees103Year Founded2020Price Target and Rating Average Price Target for Bicara Therapeutics$30.33 High Price Target$43.00 Low Price Target$8.00 Potential Upside/Downside+223.4%Consensus RatingModerate Buy Rating Score (0-4)2.72 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)($3.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$137.95 million Net MarginsN/A Pretax MarginN/A Return on Equity-49.13% Return on Assets-45.01% Debt Debt-to-Equity RatioN/A Current Ratio8.81 Quick Ratio8.81 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.17 per share Price / Book1.52Miscellaneous Outstanding Shares66,390,000Free Float57,226,000Market Cap$622.74 million OptionableOptionable Beta-0.33 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:BCAX) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.